ÂÜÀòÂÒÂ×

Dr. Jill Weimer joined Amicus in June 2019 and currently serves as the Chief Science Officer. She is a developmental neuroscientist by training and began her academic research program at Sanford Research and the University of South Dakota in 2009 as Assistant Scientist/Assistant Professor before entering her current position as Scientist/Professor. In addition to her role at Amicus, Dr. Weimer holds a leadership position at Sanford Research where she has served as Senior Director of Therapeutic Development since 2016. The work in Dr. Weimer’s lab led to the first ever gene therapy trial programs for CLN3 and CLN6 Batten disease, programs that are both now being developed by Amicus. Dr. Weimer received a B.S. and Ph.D. in neuroscience from the University of Rochester, and completed her postdoctoral training in the Neuroscience Research Center at the University of North Carolina in Chapel Hill with a focus on developmental neuroscience. Dr. Weimer also serves as a scientific advisor to a number of rare disease foundations in addition to serving as the President of the Alumni Council for the University of Rochester School of Medicine and Dentistry.